XomaZyme-791
Alternative Names: XMMCO-791/RTA; XomaZyme-ColLatest Information Update: 20 Feb 1996
Price :
$50 *
At a glance
- Originator XOMA
- Developer Cancer Research UK; Wayne State University School of Medicine; XOMA
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 20 Feb 1996 Discontinued-I for Colorectal cancer in United Kingdom (IV-infusion)
- 20 Feb 1996 Discontinued-I for Colorectal cancer in USA (IV-infusion)
- 04 Oct 1995 Phase-I clinical trials for Colorectal cancer in United Kingdom (IV-infusion)